# Exciva

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exciva

- Industry: Pharmaceuticals
- Headquarters: Heidelberg, Germany
- Website: www.exciva.com
- Total disclosed funding: $71M
- Latest round: Series B (Jul 23, 2025)
- Investors on record: 7

## About

Exciva GmbH, headquartered in Heidelberg, Germany, develops innovative therapies addressing neuropsychiatric symptoms of dementia, such as agitation and aggression in Alzheimer's patients, enhancing their quality of life through advanced medical solutions. Founded in 2015 by Anton Bespalov and Rao Vepachedu, Exciva GmbH operates from Heidelberg, Germany. In January 2026, Exciva GmbH raised EUR 51 million in series B funding co-led by Gimv and EQT Life Sciences, with participation from Fountain Healthcare Partners, LifeArc, CARMA FUND Management, and Modi Ventures, LBBW Venture Capital, Andera Partners, and others. Exciva GmbH specializes in developing innovative therapies targeting neuropsychiatric symptoms associated with dementia, particularly focusing on agitation and aggression in Alzheimer's disease patients. The company's core offerings include a groundbreaking therapy aimed at improving the quality of life for individuals experiencing these symptoms. Extensive research and clinical trials are underway to deliver first-in-class and best-in-class treatment options for dementia patients, caregivers, and families. The therapies will be utilized across various healthcare settings, including hospitals, specialized dementia care facilities, and outpatient services, with a target market in regions like North America and Europe, where dementia prevalence is significant.Exciva GmbH generates revenue through partnerships and collaborations in the healthcare sector, focusing on the development and distribution of its therapies. The company engages in strategic alliances with research institutions and healthcare providers to enhance clinical trials and effectively market its solutions. Revenue streams include direct-to-consumer sales and B2B transactions with healthcare providers and institutions. While specific pricing structures are not publicly detailed, the flagship offerings are expected to align with industry-standard pricing models indicative of their innovative nature.

## Funding rounds

- Series B, Jul 23, 2025, $60M — Andera Partners, EQT Life Sciences, Gimv, LBBW Venture Capital, Fountain Healthcare Partners, CARMA FUND Management
- Series A, Jul 28, 2021, $11M — Andera Partners, LBBW Venture Capital, Cure8 Ventures

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A, Series B
- LBBW Venture Capital (https://capitalatlas.ai/funds/lbbw-venture-capital) — Series A, Series B
- Cure8 Ventures (https://capitalatlas.ai/funds/cure8-ventures) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series B
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series B
- CARMA FUND Management (https://capitalatlas.ai/funds/carma-fund-management) — Series B